Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples
Anup Amatya(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), R. Angelo de Claro(United States Food and Drug Administration), A. K. Sinha(United States Food and Drug Administration), Harpreet Singh(United States Food and Drug Administration), Nicole Gormley(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Martha Donoghue(Center for Drug Evaluation and Research), Marc R. Theoret(United States Food and Drug Administration), Lola A. Fashoyin‐Aje(Center for Drug Evaluation and Research), Steven J. Lemery(Center for Drug Evaluation and Research), Mallorie H. Fiero(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 29
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k